Laurus Synthesis Inks Deal to Develop and Manufacture Epygenix Therapeutics’ Epilepsy Drug

Under the agreement, Laurus Synthesis will provide chemistry development services and manufacturing in support of an upcoming clinical trial evaluating EPX-100 in adolescents suffering from Dravet syndrome.

Laurus Synthesis has entered an agreement with biopharma company Epygenix Therapeutics for the development and manufacture of the lead epilepsy candidate, EPX-100. Under the agreement, Laurus Synthesis will provide chemistry development services and manufacturing in support of an upcoming clinical trial evaluating EPX-100 in adolescents suffering from Dravet syndrome. Dravet syndrome is an orphan indication with an unmet medical need.

Epygenix Therapeutics specializes in the discovery and development of drugs for the treatment of rare and intractable genetic epilepsy in childhood, such as Dravet syndrome. The company is developing  EPX-100 and EPX-200,  discovered using an in-vivo phenotypic screening system in a zebrafish model for Dravet syndrome.  These lead compounds abolish convulsive behavior and electrographic seizure activity in a Zebrafish Dravet syndrome model that mimics human pathology.

Laurus Synthesis provides drug chemistry solutions from a laboratory facility in Woburn, Massachusetts, and works synergistically with teams at Laurus Labs and Laurus Synthesis India.

Source: Laurus Synthesis